Evidence for the Presentation of Major Histocompatibility Complex Class I–restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes
Open Access
- 9 February 2004
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 199 (4), 459-470
- https://doi.org/10.1084/jem.20031219
Abstract
The Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) is expressed in all EBV-associated tumors, making it an important target for immunotherapy. However, evidence for major histocompatibility complex (MHC) class I–restricted EBNA1 peptides endogenously presented by EBV-transformed B and tumor cells remains elusive. Here we describe for the first time the identification of an endogenously processed human histocompatibility leukocyte antigen (HLA)-B8–restricted EBNA1 peptide that is recognized by CD8+ T cells. T cell recognition could be inhibited by the treatment of target cells with proteasome inhibitors that block the MHC class I antigen processing pathway, but not by an inhibitor (chloroquine) of MHC class II antigen processing. We also demonstrate that new protein synthesis is required for the generation of the HLA-B8 epitope for T cell recognition, suggesting that defective ribosomal products (DRiPs) are the major source of T cell epitopes. Experiments with protease inhibitors indicate that some serine proteases may participate in the degradation of EBNA1 DRiPs before they are further processed by proteasomes. These findings not only provide the first evidence of the presentation of an MHC class I–restricted EBNA1 epitope to CD8+ T cells, but also offer new insight into the molecular mechanisms involved in the processing and presentation of EBNA1.Keywords
This publication has 35 references indexed in Scilit:
- Self-Inhibition of Synthesis and Antigen Presentation by Epstein-Barr Virus-Encoded EBNA1Science, 2003
- Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxicBlood, 2003
- Interferon-γControl of EBV-Transformed B Cells: A Role for CD8+T Cells That Poorly Kill EBV-Infected CellsViral Immunology, 2002
- Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+T-Helper 1 ResponsesJournal of Virology, 2001
- Targeting of EBNA1 for Rapid Intracellular Degradation Overrides the Inhibitory Effects of the Gly-Ala Repeat Domain and Restores CD8+ T Cell RecognitionJournal of Biological Chemistry, 2001
- Cross-Presentation, Dendritic Cells, Tolerance and ImmunityAnnual Review of Immunology, 2001
- HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTIONAnnual Review of Immunology, 1997
- Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.The Journal of Experimental Medicine, 1996
- Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1Nature, 1995
- MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activationCell, 1994